Incyte Corporation

Stamicarbon B.v.

E.i. Dupont De Nemours and Company

Dsm N.v.

Data Security Solutions, LLC

Paul Smith

Pieter J Lemstra

Michael D Howell

Krishnaswamy Yeleswaram

Gregory Franklin Hollis

Hendrikus J Rutten

Lambert H Van Unen

Pieter B Pluyter

Jacques P Pijpers

Kurt Andrew Brown

Bruno Rotzinger

Henri D Chanzy

Fiona Kuo

Robert Kirschbaum

Beth Rumberger

Franciscus H Maurer

Allan Michael Matyger, Jr

Melissa Parker

James Fidge

Jörg Wenzel

Sean Sachen

Michael Peel

Zheng Zhang

Thomas Edward Stevenson

James Lee

Leandro Luiz Dos Santos

The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.

Treatment of hidradenitis suppurativa using JAK inhibitors

This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.

JAK1 pathway inhibitors for the treatment of prurigo nodularis

This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating gastrointestinal diseases or disorders such as ulcerative colitis.

JAK1 pathway inhibitors for the treatment of gastrointestinal disease

The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.

JAK inhibitor with a vitamin D analog for treatment of skin diseases

The present application provides methods of treating a disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a JAK1 selective inhibitor, or a pharmaceutically acceptable salt thereof.

Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)

This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.

JAK1 pathway inhibitors for the treatment of vitiligo

The present application provides combination therapies comprising a JAK inhibitor and a ROCK inhibitor, and methods of using the same to treat disorders such as graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), and systemic sclerosis (scleroderma).

Combination therapy comprising JAK pathway inhibitor and rock inhibitor

A method and system of making information from an application accessible to an electronic device, comprising: checking, via a log monitor, a third party log file for a new log entry; sending any new log entries in the third party log file to a rules engine, the rules engine comprising at least one rule; determining if any of the new log entries violate any rules in the rules engine; making accessible any new log entries that violate any rules to the electronic device; creating an alert based on the new log entry that violates at least one rule; and notifying users of the alert using alert criteria to determine who should receive the alerts and when, wherein different users receive different alerts based on the alert criteria.

Method and system for providing information from third party applications to devices

The invention relates to microporous films of ultrahigh molecular weight polyethylene and to a process for the preparation thereof by forming a solution of UHMWPE in an evaporable solvent into a film and evaporating the solvent from the film at a temperature below the dissolution temperature, the shrinking tendency occurring in the film being prevented in at least one direction in the plane of the film.

Process for making microporous films of ultrahigh molecular weight

Process of making microporous films of UHMWPE

High strength, substantially linear, highly crystalline, high molecular weight-polyolefin shaped structure having a tenacity of greater than 15 g/den and an initial modulus of greater than 500 g/den by drawing never-processed polyolefin at a temperature of 60.degree. C. to 145.degree. C.; and processes for making never-processed polyolefin and such shaped structures.

Production of substantially linear highly crystalline polyolefins

High strength polyolefins

An improved process for the preparation of polymer filaments having a high tensile strength and modulus by spinning a solution of high-molecular weight polymer and thereafter stretching the filament thus formed. A solution of an ethylene polymer or copolymer, containing at least 80 percent by weight solvent, is spun at a temperature above the gel point of the solution. The ethylene polymer or copolymer contains at most about 5 percent by weight of an alkene having 3 to 8 carbon atoms, has a weight-average molecular weight Mw higher than 4.times.10.sup.5 kg/kmole, and has a weight/number average molecular weight ratio Mw/Mn lower than 5. The spun polymer solution is thereafter cooled to a temperature below its gel point to form a gel filament, which gel filament is thereafter stretched to form a polymer filament having a tensile strength of at least about 1.5 GPa at room temperature.

Process for the production of polymer filaments having high tensile

Growing community of inventors

Wilmington, DE, United States of America

Paul Smith